Common Stock, $0.0001 par value per share
- Symbol
- ALMS
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.07 · 8-K
Alumis Inc.
ALMSNASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 30, 2026, Alumis Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of May 5, 2026, the record date for the Annual Meeting, 123,432,072 shares of voting common stock were outstanding and entitled to vote at the Annual Meeting.…
Company context
Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases, such as Parkinson’s disease. In addition, the pipeline includes several preclinical programs identified through this precision approach. For more information, visit www.alumis.com or follow us on LinkedIn or X.
Current securities
Registered securities in this filing
Alumis Inc. · 8-K · Filed 2026-07-02
Disclosure sections
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 30, 2026, Alumis Inc. (the “Company”)
held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of May 5, 2026, the record date for the Annual Meeting,
123,432,072 shares of voting common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted
upon by stockholders at the Annual Meeting is set forth below. A more complete description of each matter can be found in the Company’s
definitive proxy statement filed with the U.S. Securities and Exchange Commission on May 18, 2026.
Proposal 1: Election of Directors
James B. Tananbaum, Lynn Tetrault and Zhengbin
(Bing) Yao were elected as Class II directors, to hold office until the 2029 Annual Meeting of Stockholders. The final voting results
are as follows:
Name of Director Elected Votes For Votes Withheld Broker Non-Votes
─────────────────────────────────────────────────────────────────────────────────────────
James B. Tananbaum, M.D. 85,906,705 1,718,328 18,824,099
Lynn Tetrault, J.D. 87,361,666 263,367 18,824,099
Zhengbin (Bing) Yao, Ph. D. 73,694,150 13,930,883 18,824,099
Proposal 2: Ratification of Appointment of
the Company’s Independent Auditor
The Company’s stockholders ratified the
appointment by the Company’s Audit Committee of PricewaterhouseCoopers LLP as the Company’s independent auditor for the fiscal
year ending December 31, 2026. The final voting results are as follows:
Votes For Votes Against Abstentions
────────────────────────────────────────────────────────────────────────────────────────────
105,924,017 283,113 242,002